| Outcome Measures: |
Primary: Mean Absolute Change in Hb levels, The primary endpoint is the mean absolute change in Hb levels between the screening/baseline period (Week -2 to Day 1 of Week 1) and the evaluation period (Week 21 to Week 24). Hb level at screening/baseline period is defined as the mean of the Hb measurements at screening and on Day 1 of Week 1 (prior to dosing). Hb level at evaluation period is defined as the mean of the Hb measurements at Week 21, 22, 23, and 24 (in detail, Day 1 of Week 21, Day 1 of Week 22, Day 1 of Week 23, and Day 1 of Week 24)., Week -2~Week 1 (Prior to Dose), Week 1, Week 21, Week 22, Week 23, Week 24 | Secondary: Hemoglobin Responder Rate, Week -2~Week 1 (Prior to Dose), Week 1, Week 21, Week 22, Week 23, Week 24|Mean EPO dosage (Week 1 to Week 24), Week 1 ~ Week 24|Mean EPO dosage (Week 21 to Week 24), Week 21 ~ Week 24 | Other: Safety: Any adverse events, Any adverse events, Week 1 to Week 52|Immunogenicity: Anti-drug antibody (ADA) response by Week 52 compared to baseline (Week -2~Week 1 (Prior to Dose)), Anti-drug antibody (ADA) response by Week 52 compared to baseline (Week -2\~Week 1 (Prior to Dose)), (Week -2~Week 1 (Prior to Dose)), Week 52
|
